Takeda Presents Phase 2/3 TAK-881 Trial Results at ESID 2026
Takeda presented results from the pivotal Phase 2/3 IgGNITE trial evaluating investigational TAK-881 for primary immunodeficiency disease.
Story updates
12:01:29 PM UTC
SquawkNews
Takeda reported detailed Phase 2/3 IgGNITE results showing TAK-881 met PK comparability vs HYQVIA and cut infusion volume by 50% with shorter times while maintaining up to once—monthly dosing in PID. Regulatory filings are expected in FY2026.Material DetailsContext by AI AnalystThis is a pivotal re…